Introduction to the latest price and purchasing channels of Telisotuzumab

Telisotuzumab (Telisotuzumab vedotin, trade nameEmrelis) is an innovative antibody drug conjugate (ADC) that mainly targets c-MetThe protein has now received accelerated approval from the USFDA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high expression of c-Met. With the development of precision cancer medicine, terituzumab has received widespread attention due to its strong targeting and significant efficacy. This article will comprehensively introduce the relevant information of territuzumab from four aspects: drug introduction, latest price, purchasing channels and clinical application prospects.

1. Drug introduction and mechanism of action of territuzumab

Territuzumab is an antibody-drug conjugate composed of an anti-c-Met monoclonal antibody and the cytotoxic drug monomethyl auristatinE (MMAE) via a stable linker. c-Met is a receptor tyrosine kinase that is widely involved in key processes of tumor development such as cell proliferation, migration, invasion and angiogenesis. In a variety of tumors, c-Metoverexpression or genetic abnormalities are closely related to tumor malignancy and drug resistance.

Territuzumab specifically binds to c-Met and accurately delivers potent cytotoxic drugs into tumor cells. It releases MMAE and then destroys the microtubule skeleton, inducing cell cycle arrest and tumor cell apoptosis, thereby effectively killing c-Met positive tumor cells. This dual mechanism of "targeting + poisoning" greatly improves drug selectivity and therapeutic effect, and reduces toxic and side effects on normal cells.

2. The latest price of territuzumab

As an innovativeADC drug, the price of terituzumab is relatively high, reflecting its research and development costs and clinical value. According to 2025 market data, the price of research-grade terituzumab is approximately 400 to 1100USD, 100microgram price is about 220USD. Specific to clinical drugsEmrelis, its pricing fluctuates due to differences in regions, suppliers, medical insurance policies, etc., but overall it is at the level of high-end targeted drugs.

In the United States, Emrelis is mainly provided through prescription and medical insurance coverage. The manufacturer AbbVie has also launched a patient assistance program to help patients with financial difficulties reduce medication costs. Although the price of the drug is relatively high, its clinical value is widely recognized due to its significant prolongation of progression-free survival and improvement of quality of life in patients with high expression of c-MetNSCLC.

3. Purchase channels for territuzumab

For scientific and clinical research use, terituzumab is available through several biotechnology companies and specialty suppliers, such asAbMole BioScience, MedChemExpress, Selleck Chemicals and Invitrogen, etc. These channels provide products of different specifications and purity, support international distribution, and meet the needs of scientific research and early clinical trials.

For clinical use by patients, Emrelis is mainly obtained through hospitals, professional pharmacies and officially authorized distributors. In the U.S. market, McKesson’s biologics division is responsible for the distribution of Emrelis, and patients need to purchase it through regular medical institutions with a doctor’s prescription. In addition, patient assistance programs and medical insurance reimbursement policies have also alleviated the financial pressure of medication to a certain extent.

In China, since it has not been officially approved for marketing, patients can only obtain it through overseas medical channels, international clinical trials or imported drug purchasing. Such methods involve legal compliance risks and financial burdens. Patients should choose carefully and it is best to use them rationally under the guidance of a professional doctor.

4. Clinical Application Prospects and Development

Territuzumab, as a precision targeting ADC drug, brings new treatment hope to patients with c-Met positive non-small cell lung cancer. Its unique drug coupling mechanism effectively overcomes the resistance problem of traditional targeted drugs and significantly improves the efficacy. As more clinical data accumulates, the drug's indications are expected to be further expanded to other solid tumors with abnormal expression of c-Met, such as renal cancer, gastric cancer, etc.

In the future, terituzumab may be used in combination with immune checkpoint inhibitors, chemotherapy drugs, etc. to achieve multi-modal treatment and improve the overall survival rate of patients. At the same time, as China's drug regulatory authorities optimize the approval process for innovative drugs, terituzumab is expected to be launched in China earlier, providing good news to more patients.

In summary, terituzumab has become an important breakthrough in the treatment of non-small cell lung cancer due to its advantages of precise targeting and significant efficacy. Although the current price is relatively high and it has not yet been launched in China, with the in-depth clinical research and market promotion, it is expected to bring a wider range of treatment options and better quality of life to the majority of cancer patients. Patients should pay attention to the latest drug trends, actively communicate with doctors, and jointly develop scientific and reasonable treatment plans.

Reference materials:https://www.drugs.com/